| Sep 30 |
Invesco EQV European Equity Fund Bolsters Position in Teva Pharmaceutical with a 1. ...
|
| Sep 28 |
Here are the Medicare Part D drugs expected to face 2025 price negotiations
|
| Sep 27 |
Amazon to provide opioid overdose drug in workplace
|
| Sep 25 |
FTC weighs in on reverse-payment generic delay case involving Gilead, Teva
|
| Sep 23 |
Teva touts safety profile of once monthly schizophrenia therapy
|
| Sep 23 |
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
|
| Sep 21 |
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
|
| Sep 21 |
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
|
| Sep 19 |
Teva Pharmaceutical Industries Limited (TEVA) Bank of America Global Healthcare Conference (Transcript)
|
| Sep 15 |
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is favoured by institutional owners who hold 68% of the company
|
